RxDoctor Payments Data

Jada Kitchen

Family · Washington Court House, OHNPI 1811181936

Payments from drug & device makers

$2,552in general payments, 2019–2025

Across 137 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$465
  • Novo Nordisk$392
  • Merck$384
  • Lilly USA, LLC$318
  • AstraZeneca$314
  • Abbott$100
  • plus $579 from 17 others

What the payments were for

  • Food & beverage$2,48697%
  • Education$663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,552 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$129,340
JardianceEmpagliflozin89$81,877
MounjaroTirzepatide55$66,409
TrulicityDulaglutide57$61,679
JanuviaSitagliptin Phosphate14$23,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,272
EliquisApixaban15$17,318
Tresiba Flextouch U-100Insulin Degludec25$9,275
SymbicortBudesonide/Formoterol Fumarate33$8,180
FarxigaDapagliflozin Propanediol12$6,625
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$4,205
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$3,206
Gabapentin202$2,723
Ezetimibe83$2,508
Atorvastatin Calcium282$2,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$392$129,340127 claims
Lilly USA, LLCMounjaro, Trulicity$318$128,088112 claims
Boehringer IngelheimJardiance$35$81,87789 claims
MerckJanuvia$384$23,10414 claims
GSKTrelegy Ellipta$17$21,27219 claims
PfizerEliquis$91$17,31815 claims
AstraZenecaSymbicort, Farxiga$314$14,80545 claims
AbbVieSynthroid$465$1,26325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Washington Court House

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →